Oskar Hansson
221 – 230 of 565
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
Current advances in plasma and cerebrospinal fluid biomarkers in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Clinical validity of increased cortical uptake of [18F]flortaucipir on PET as a biomarker for Alzheimer’s disease in the context of a structured 5-phase biomarker development framework
(
- Contribution to journal › Scientific review
-
Mark
Untangling the association of amyloid-β and tau with synaptic and axonal loss in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework
(
- Contribution to journal › Scientific review
-
Mark
Early stages of tau pathology and its associations with functional connectivity, atrophy and memory
(
- Contribution to journal › Article
-
Mark
Genetic effects on longitudinal cognitive decline during the early stages of Alzheimer’s disease
(
- Contribution to journal › Article
- 2020
-
Mark
Cerebrospinal fluid neurogranin in an inducible mouse model of neurodegeneration : A translatable marker of synaptic degeneration
(
- Contribution to journal › Article
-
Mark
Apathy and anxiety are early markers of Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Head-to-head comparison of tau positron emission tomography tracers [18F]flortaucipir and [18F]RO948
(
- Contribution to journal › Article
-
Mark
Distinct tau PET patterns in atrophy-defined subtypes of Alzheimer's disease
(
- Contribution to journal › Article